Rain Therapeutics Inc. (NASDAQ:RAIN) Receives Average Rating of “Buy” from Analysts

Shares of Rain Therapeutics Inc. (NASDAQ:RAINGet Rating) have been given an average recommendation of “Buy” by the seven research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $22.20.

Separately, Oppenheimer began coverage on Rain Therapeutics in a research report on Thursday, March 31st. They issued an “outperform” rating and a $15.00 target price on the stock.

Rain Therapeutics stock opened at $2.30 on Tuesday. Rain Therapeutics has a 12 month low of $2.22 and a 12 month high of $22.22. The stock’s 50 day moving average is $4.92 and its 200-day moving average is $9.12. The company has a market capitalization of $60.97 million and a price-to-earnings ratio of -0.95.

Rain Therapeutics (NASDAQ:RAINGet Rating) last posted its earnings results on Wednesday, May 4th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.02. During the same period last year, the company posted ($1.93) earnings per share. Sell-side analysts predict that Rain Therapeutics will post -2.53 EPS for the current year.

Large investors have recently modified their holdings of the stock. Citigroup Inc. grew its position in Rain Therapeutics by 539.7% during the fourth quarter. Citigroup Inc. now owns 5,572 shares of the company’s stock worth $72,000 after buying an additional 4,701 shares in the last quarter. Wells Fargo & Company MN acquired a new stake in Rain Therapeutics during the fourth quarter worth approximately $98,000. California State Teachers Retirement System grew its position in Rain Therapeutics by 88.6% during the fourth quarter. California State Teachers Retirement System now owns 8,719 shares of the company’s stock worth $112,000 after buying an additional 4,096 shares in the last quarter. Deutsche Bank AG grew its position in Rain Therapeutics by 122.4% during the fourth quarter. Deutsche Bank AG now owns 9,669 shares of the company’s stock worth $125,000 after buying an additional 5,321 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Rain Therapeutics in the 4th quarter valued at $129,000. 70.51% of the stock is currently owned by institutional investors and hedge funds.

About Rain Therapeutics (Get Rating)

Rain Therapeutics Inc, a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers.

Featured Articles

Analyst Recommendations for Rain Therapeutics (NASDAQ:RAIN)

Receive News & Ratings for Rain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.